Castle Biosciences (CSTL) CCO Juvenal Tobin Sells Shares

What Happened Juvenal Tobin W, Chief Commercial Officer of Castle Biosciences (CSTL), sold a total of 6,600 shares in two open-market transactions: 3,306 shares on 2026-09-14 at a weighted-average price of $32.32 for $106,863, and 3,294 shares on 2026-09-15 at a weighted-average price of $35.14 for $115,758. The combined proceeds were about $222,621. These were sales (not purchases) executed under a pre-established trading plan.

Key Details

• Transaction dates & prices:
  • 2026-09-14: 3,306 shares sold, weighted-average $32.32 (actual trades ranged $32.180–$32.445). (Footnote F2)
  • 2026-09-15: 3,294 shares sold, weighted-average $35.14 (actual trades ranged $35.000–$35.380). (Footnote F3)
• Total shares sold: 6,600; total proceeds: ~$222,621.
• Plan: Transactions were made under a Rule 10b5‑1 plan adopted May 28, 2026. (Footnote F1)
• Filing: Form 4 filed 2026-09-16; appears timely relative to the transaction dates.
• Shares owned after the transactions: not reported in the data provided here.

Context

• A 10b5‑1 plan indicates these sales were made under a prearranged schedule — common for executives to reduce timing risk; such sales may not reflect the insider’s current view of the company.
• These were outright stock sales (code S). Sales are generally treated as routine cashing‑out activity rather than an affirmative bullish signal; purchases are typically more informative about insider sentiment.